Table 1. Tumor incidence, survival, and spectrum in p53^+/− mice with secondary CIN-inducing mutations.

Tumor incidence is shown as percentage of cohort with tumor in double mutants versus p53^+/− mice, respectively. Median tumor free survival is shown as the median survival of the double mutant cohort versus the p53^+/− cohort, respectively. Studies in which effect on tumor phenotype is listed as unchanged are those in which incidence and/or survival between p53^+/− and doubly mutant mice did not reach statistical significance.

Secondary Mutation	Tumor Incidence	Median Tumor Free Survival (days)	Primary Tumor Type^$	Effect on Tumor Phenotype	Reference
Bub1^{+/H ^}	57% vs 43%	495 vs 471^*	sarcoma	Unchanged	(Baker et al., 2009)
Bub1^+/−	57% vs 43%	469 vs 471^*	sarcoma	Unchanged
Bub1^H/H	78% vs 43%	346 vs 471^*	lymphoma	Exacerbated
Bub1^−/H	76% vs 43%	202 vs 471^*	lymphoma	Exacerbated
Bub3^+/−	47% vs 62%	~560 vs ~525	osteosarcoma	Unchanged	(Kalitsis et al., 2005)
Mad1^+/−	76% vs 67%		osteosarcoma	Unchanged	(Chi et al., 2009)
Mad2^+/−	88% vs 67%		lymphoma	Exacerbated
Mad1^+/−;Mad2^+/−	95% vs 67%		osteosarcoma	Exacerbated
Mad1^+/−;Mad2^+/−	25% vs 53% in Mad2^+/−;p53^+/−^#		osteosarcoma	Suppressed
Separase OE MMTV-LTR promoter (mammary)	100%	439 vs ~580	mammary carcinoma	Exacerbated	(Mukherjee et al., 2014)
Separase^+/H	100% vs ~50%	460 vs ~530		Exacerbated	(Mukherjee et al., 2011)
Mps1^f/f p53^f/+; Lck-Cre (T cells)^&	100% vs ~0% in p53^f/+;Lck-Cre	~105 vs >360	T-cell acute lymphoblastic lymphoma	Exacerbated	(Foijer et al., 2014)
Plk4 OE;p53^f/+; ERT-CRE (β-actin promoter)		~565 vs ~575	lymphoma	Unchanged	(Vitre et al., 2015)

the primary tumor type in p53^+/− animals is sarcoma

^{^}

H indicates a hypomorphic allele

average tumor latency

lymphoma incidence

f indicates a floxed allele

Table 1. Tumor incidence, survival, and spectrum in p53+/− mice with secondary CIN-inducing mutations.

Table 1. Tumor incidence, survival, and spectrum in p53^+/− mice with secondary CIN-inducing mutations.